• NORTH CAROLINA SOCIETY OF GASTROENTEROLOGY
  • 704.376.3688
  • sbuchanan@meckmed.org
NCSGlogo-300NCSGlogo-only-150NCSGlogo-300NCSGlogo-300
  • Home
  • Events and Education
  • Research
  • About NCSG
    • Board of Directors
    • Board Meetings
    • Grants
    • Partners
    • NCSG Bylaws
JOIN or RENEW HERE
✕
Categories
  • Eosinophilic Esophagitis
Tags
  • Eosinophilic Esophagitis

 

Study title A Multi-center, Randomized, Double-blind, Parallel-group, Placebo-controlled 3-Part Phase 3 Study to Demonstrate
the Efficacy and Safety of Benralizumab in Patients with Eosinophilic Gastritis and/or Gastroenteritis (The HUDSON GI Study)
Disease or condition Eosinophilic Gastritis and/or Gastroenteritis
Study type Interventional (Clinical Trial)
Intervention/treatment Benralizumab or placebo
Phase 3
Study site University of North Carolina at Chapel Hill
Study location Chapel Hill
Principal investigator name and email Evan Dellon, MD, MPH cedas@med.unc.edu
Study coordinator name and email Tim Gee, timsgee@email.unc.edu
Phone contact  (919) 445-0747
Clinicaltrials.gov link  

ADDRESS


1112 Harding Place
Suite 100
Charlotte NC 28204

Fax: 704.376.3173

LINKS


Home
Education
Events
Research
JOIN NOW

CONTACT


704.376.3688
sbuchanan@meckmed.org

Copyright: North Carolina Society of Gastroenterology (NCSG)
JOIN or RENEW HERE